Details of the Drug
General Information of Drug (ID: DMO2UKI)
| Drug Name |
SP-MET-1
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | S1004A receptor antagonist (cancer), Supratek; SP-MET-X1; Antimetastatic agent (oral, cancer), Supratek; S1004A receptor antagonist (oral, melanoma/breast/colorectal cancer), Supratek | ||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||

